State Street Corp Decreases Stock Holdings in Theravance Biopharma, Inc. (NASDAQ:TBPH)

State Street Corp lowered its stake in Theravance Biopharma, Inc. (NASDAQ:TBPH) by 6.0% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 1,191,621 shares of the biopharmaceutical company’s stock after selling 75,754 shares during the quarter. State Street Corp owned 2.44% of Theravance Biopharma worth $9,604,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in TBPH. Quantbot Technologies LP acquired a new position in shares of Theravance Biopharma during the 3rd quarter worth about $60,000. China Universal Asset Management Co. Ltd. raised its holdings in shares of Theravance Biopharma by 64.7% during the third quarter. China Universal Asset Management Co. Ltd. now owns 9,409 shares of the biopharmaceutical company’s stock valued at $76,000 after acquiring an additional 3,696 shares during the last quarter. Ballentine Partners LLC purchased a new position in shares of Theravance Biopharma in the third quarter valued at approximately $104,000. Hsbc Holdings PLC purchased a new position in shares of Theravance Biopharma in the second quarter valued at approximately $108,000. Finally, XTX Topco Ltd purchased a new stake in shares of Theravance Biopharma during the second quarter worth approximately $129,000. Hedge funds and other institutional investors own 99.10% of the company’s stock.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and issued a $15.00 price objective on shares of Theravance Biopharma in a report on Monday, September 16th. Four equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $13.75.

Insider Activity at Theravance Biopharma

In other Theravance Biopharma news, SVP Rhonda Farnum sold 4,000 shares of the company’s stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $9.00, for a total value of $36,000.00. Following the transaction, the senior vice president now owns 322,743 shares of the company’s stock, valued at $2,904,687. This represents a 1.22 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. 6.90% of the stock is currently owned by insiders.

Theravance Biopharma Stock Up 0.1 %

Shares of NASDAQ:TBPH opened at $9.86 on Friday. Theravance Biopharma, Inc. has a 52-week low of $7.44 and a 52-week high of $11.71. The business has a fifty day moving average of $9.32 and a two-hundred day moving average of $8.84. The stock has a market cap of $484.86 million, a P/E ratio of -9.76 and a beta of 0.23.

Theravance Biopharma (NASDAQ:TBPH) last issued its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.16). Theravance Biopharma had a negative return on equity of 24.79% and a negative net margin of 78.18%. The firm had revenue of $16.87 million for the quarter, compared to analysts’ expectations of $16.11 million. During the same period last year, the firm earned ($0.17) earnings per share. On average, equities analysts anticipate that Theravance Biopharma, Inc. will post -1.09 earnings per share for the current year.

Theravance Biopharma Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.